Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021.

Bradley, Marie C; Perez-Vilar, Silvia; Chillarige, Yoganand; Dong, Diane; Martinez, Ashley I; Weckstein, Andrew R; Dal Pan, Gerald J

Bradley, Marie C; Perez-Vilar, Silvia; Chillarige, Yoganand; Dong, Diane; Martinez, Ashley I; Weckstein, Andrew R; Dal Pan, Gerald J.

Afiliación

Bradley MC; Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
Perez-Vilar S; Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
Chillarige Y; Acumen LLC, Burlingame, California.
Dong D; Department of Veterans Affairs Center for Medication Safety, Hines, Illinois.
Martinez AI; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
Weckstein AR; Aetion Inc, New York, New York.
Dal Pan GJ; Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.

JAMA ; 327(20): 2015-2018, 2022 05 24.

Article en En | MEDLINE | ID: mdl-35394487

Asunto(s)

Tratamiento Farmacológico de COVID-19; Glucocorticoides; Atención Ambulatoria; Glucocorticoides/uso terapéutico; Humanos; Estudios Retrospectivos; SARS-CoV-2; Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 / Glucocorticoides Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: JAMA Año: 2022 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google